Yimei concept stocks all weakened, Aoyuan Meigu closed down

Synthetic Biology: Who Will Emerge as the Winner?

The 21st century is the century of biology. Synthetic biology is believed to be a ‘World Changing’ industry. But the potential risks like cost control and commercialization pathways are fatefully tied to the ups and downs of countless investment decisions and the destiny of the many new start-ups getting involved. We look forward to seeing an emerging ‘giant’ on the horizon of this exciting industry.

Mabwell Signs GCC Licensing Deal with Saudi Arabia’s SVAX for Aflibercept Biosimilar

Mabwell (Shanghai) Bioscience Co., Ltd.（迈威（上海）生物科技股份有限公司）has entered into a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc. covering its aflibercept biosimilar, 9MW0813, in the Gulf Cooperation Council market.

Insilico Medicine (英矽智能) Signs Strategic Drug Discovery Partnership with Takeda (武田制药), Deal Worth Up to US$600 Million

Chinese AI drug discovery company Insilico Medicine (英矽智能) has signed a global strategic collaboration with Japanese pharmaceutical company Takeda (武田制药), with the total potential deal value reaching up to US$600 million. Announced in early July, the agreement marks another milestone in the international commercialization of China's AI-powered drug discovery technologies through collaboration with a leading multinational pharmaceutical company.

Drug Farm Raises $55 Million in First Closing of Series D Financing

According to EO (亿欧), Drug Farm (药物牧场) announced on July 13 that it had raised $55 million in the first closing of its Series D financing round.

Bloomage: Injecting Biotechnology into Beauty Care

Listed on the Chinese Star Market in November 2019, Bloomage was trading at CNY 138.01 as of June 24, 2020, over 38% higher than the IPO price of CNY 100.